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Background: The transcription factor E2F1 has been implicated in cell cycle control and DNA damage response.
Paradoxically, E2F1 can promote apoptosis and function as tumor suppressor. In non-small cell lung cancer (NSCLC),
there are conflicting data for clinical significance of E2F1 expression. In this study, we investigated the protein
expression of E2F1 in patients with stage I-III NSCLC, and its correlation with clinical outcome.
Results: 56 paired adjacent non-tumor/tumor matched samples were prospectively obtained from patients
undergoing surgery for stage I-III NSCLC at Taipei Veterans General Hospital. The protein expression of E2F1 was
determined by Western blot analysis. The levels of E2F1 protein were significantly higher in tumor samples than in
non-tumor lung specimens (P= 0.008). Overexpression of E2F1 was defined as a more than 2-fold expression in the
tumorous sample compared with the corresponding nontumorous one, and was noted in 21 patients (37.5%).
There was no significant difference in overall survival (P= 0.44) or probability of freedom from recurrence (P= 0.378)
between patients with E2F1 overexpression vs. non-overexpressors. Additionally, there was no significant association
between E2F1 overexpression and any clinicopathologic parameter such as histological type, stage, or
angiolymphatic invasion of tumor.
Conclusion: E2F1 protein is frequently overexpressed in NSCLC. There is no correlation between E2F1 protein
expression and clinical outcome such as survival and freedom from progression.
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Lung cancer is the leading cause of cancer-related death
globally, and non-small cell lung cancer (NSCLC)
accounts for more than 80% of all lung cancers. Despite
of advances in biomedical science, surgery remains the
mainstay of treatment for early-stage NSCLC, and the
result of surgical treatment alone is unsatisfactory.
Therefore, there is an urgent need to identify biomarkers
for prognostication of patients’ outcome after surgery.
Prognostic markers can be used to select patients with
increased risk of recurrence who may require more
frequent surveillance and derive more benefit from
adjuvant treatment. Many prognostic markers have
been investigated in NSCLC such as mutation status of* Correspondence: wuyc@vghtpe.gov.tw
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reproduction in any medium, provided the orKRAS and p53, and expression of excision repair cross-
complementation group 1 and ribonucleotide reductase
subunit M1 [1-3].
E2F1 belongs to the E2F family of transcription factors,
and plays an important role in cell cycle progression and
apoptosis [4]. Besides cell cycle regulation, E2F1 partici-
pates in DNA damage response and functions as a
checkpoint control [5]. Increased E2F1 protein level
associated with DNA damage and repair is observed in
NSCLC cells after exposure to cisplatin [6]. Furthermore,
E2F1 can induce apoptosis by both a p53-independent
mechanism (mediated by p73) and a p53-dependent
mechanism in cancer cell lines [7,8]. Development of
NSCLC and lymphoma has been observed in mice lack-
ing E2F1, indicating the role of tumor suppressor for
E2F1 [9,10].
Dysregulation of E2F1 is frequently seen in cancers. It
seems that E2F1 plays a dual role in terms of promoting
tumor growth and inducing apoptosis. For example,
E2F1 overexpression is associated with better clinicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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der cancer, tongue cancer, gastric cancer and esophageal
adenocarcinoma [11-15]. Whereas in breast and thyroid
neoplasms, increased E2F1 expression is associate with
higher proliferation index and more aggressive profile
[16,17]. For NSCLC, conflicting data about the prognostic
value of E2F1 expression exist in patients undergoing
surgery for stage I-III disease. Volm et al. have exam-
ined E2F1 expression in 96 patients with squamous-cell
lung carcinoma by immunohistochemistry (IHC), and
found no correlation between the E2F1 expression and
survival [18]. Huang and others have studied E2F1 gene
expression by quantitative RT-PCR in 127 patients with
NSCLC, and found adverse clinical outcomes in patients
with E2F1 overexpression [19]. These findings imply
E2F1 could be a double-edged sword, and more study is
needed to explore its role as a prognostic marker in
NSCLC. Herein, we investigated the clinical significance
of E2F1 protein expression by Western blot analysis in a
cohort of patients with stage I-III NSCLC undergoing
surgical resection.
Results and discussion
After surgery, the patients were followed regularly with
physical examination and imaging study. The mean
follow-up duration for all the 56 patients was
54.6 ± 34.1 months. The characteristics of these patients
are listed in Table 1. There were 4 patients undergoing
adjuvant chemotherapy, 7 undergoing adjuvant radio-
therapy, and 2 receiving adjuvant chemoradiation ther-
apy. At the last follow-up, 26 (46.4%) were free of tumor
recurrence, 27 (48.2%) developed recurrence, and 3
(5.4%) patients had unknown recurrence status.
A total of 56 pairs of matched fresh frozen tumor spe-
cimens and non-tumor normal lung tissues were used
for Western blot analysis. The representative results of
Western immunoblotting in 5 pairs of specimens were
shown in Figure 1. As shown in Table 2, the mean E2F1
protein expression in tumors and non-tumor lung tis-
sues were 0.33 ± 0.04 and 0.19 ± 0.02, respectively. The
mean E2F1 protein expression in normal lung tissues
was. E2F1 protein expression was significantly higher
in tumor specimens than in normal lung tissues (paired
t-test, P= 0.008).
Overexpression of E2F1, defined as a more than 2-fold
expression in the tumorous sample compared with the
paired non-tumor tissue, was noted in 21 (37.5%)
patients. As shown in Figure 2, the overall survival and
probability of freedom from recurrence were not signifi-
cantly different between patients with and without E2F1
overexpression (P = 0.440 and 0.378, respectively). We
also analyzed the prognostic value of E2F1 expression
in patients with NSCLC stratified by different stages.
For patients with stage I NSCLC, the overall survivaland probability of freedom from recurrence were not
significantly different between patients with and without
E2F1 overexpression (P= 0.385 and 0.306, respectively).
For patients with stage II/III NSCLC, the overall survival
and probability of freedom from recurrence were not
significantly different between patients with and without
E2F1 overexpression (P= 0.782 and 0.874, respectively).
We further investigated the relationship between clinico-
pathological variables and E2F1 protein expression.
There was no significant association between histolog-
ical type and E2F1 expression (P= 0.906). Additionally,
there was no relationship between E2F1 protein expres-
sion and other variables such as age, gender, smoking
index, tumor size, T descriptor, N descriptor, stage,
angiolymphatic invasion of tumor, and histological grade
(Table 1).
We have summarized all 4 studies investigating clinical
significance of E2F1 expression in patients undergoing
surgical resection for stage I, II and III NSCLC (Table 3).
Volm et al. used IHC to study E2F1 protein expression
in 96 patients with squamous cell carcinoma of lung,
and found no significant difference in survival between
patients with E2F1 overexpression (IHC +++) and E2F1
non-overexpressors (IHC −/+/++)[18]. Gorgoulis and
colleagues used IHC in 77 patients, and found signifi-
cantly decreased survival in patients with above-median
E2F1 protein immunoreactivity [20]. Huang et al.
reported that increased E2F1 RNA expression was cor-
related with decreased survival in 127 patients [19].
However, for 57 patients with stage I NSCLC, they did
not observe any correlation between survival and E2F1
RNA expression.
Although dysregulation of E2F1 is frequently observed
in cancers, it is controversial whether E2F1 participates
in oncogenic events to promote tumor growth or func-
tions as a tumor suppressor controlling checkpoint to
induce apoptosis [4]. E2F1 overexpression has been
shown to be a poor prognostic marker in squamous cell
carcinoma of esophagus [21]. However, it has also been
demonstrated that increased E2F1 expression correlates
with better clinical outcomes in many cancer types such
as lymphoma, urinary bladder cancer, tongue cancer,
gastric cancer, esophageal adenocarcinoma, colon cancer
and breast cancer [11-15,22,23]. In addition to our sum-
mary in Table 3 for NSCLC, controversies on the clinical
significance of E2F1 expression are noted in breast can-
cer as well [22,24].
The regulatory mechanism of E2F1 gene expression is
complex, and frequently involves both transcriptional
and post-transcriptional pathways. The regulation of
E2F1 protein levels could be mediated through
ubiquitin-proteasome-dependent degradation. UCN-01,
a protein kinase C/CDK inhibitor, is a potential antican-
cer agent. We have previously shown that UCN-01
Table 1 Characteristics of 56 patients with non-small cell lung cancer and the relationship between E2F1 protein
expression and clinicopathological variables
Variables Total (n = 56) E2F1 protein expression
Low (n = 35) High (n= 21) P value
Age at operation, years 65.9 ± 11.1 66.8 ± 10.0 64.6 ± 12.8 NS
Gender
Male 41 (73.2) 27 (77.1) 14 (66.7) NS
Female 15 (26.8) 8 (22.9) 7 (33.3)
Smoking index, pack-years 25.1 ± 32.0 29.6 ± 36.1 17.9 ± 23.1 NS
Tumor size, cm 4.0 ± 1.6 4.0 ± 1.7 3.8 ± 1.5 NS
Histological type
Squamous cell carcinoma 20 (35.7) 14 (40.0) 6 (28.6) NS
Adenocarcinoma 33 (58.9) 20 (57.1) 13 (61.9)
Others 3 (5.4) 1 (2.9) 2 (9.5)
T descriptor
T1 7 (12.5) 3 (8.6) 4 (19.0) NS
T2 38 (67.9) 25 (71.4) 13 (61.9)
T3 4 (7.1) 1 (2.9) 3 (14.3)
T4 7 (12.5) 6 (17.1) 1 (4.8)
N descriptor
N0 33 (58.9) 20 (57.1) 10 (61.9) NS
N1 10 (17.9) 8 (22.9) 4 (9.5)
N2 13 (23.2) 7 (20.0) 7 (28.6)
Stage
I 26 (46.4) 16 (45.7) 10 (47.6) NS
II 10 (17.9) 6 (17.1) 4 (19.0)
III 20 (35.7) 13 (37.2) 7 (33.4)
Angiolymphatic invasion
Absent 38 (67.9) 23 (67.6) 15 (75.0) NS
Present 16 (28.5) 11 (32.4) 5 (25.0)
Unknown 2 (3.6)
Histological grade
Well differentiated 4 (7.1) 3 (8.6) 1 (5.3) NS
Moderately differentiated 36 (64.3) 23 (65.7) 13 (68.4)
Poorly differentiated 14 (25.0) 9 (25.7) 5 (26.3)
Unknown 2 (3.6)
NS not significant.
Continuous variables are expressed as mean ± SD; categorical variables are expressed as N (%).
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through a ubiquitin-proteasome-dependent pathway in
gastric cancer cells [25]. Translation of E2F1 mRNA can
be regulated by microRNA system in cancer [26,27].
Cho and colleagues recently have identified that methy-
lation of E2F1 protein by protein arginine methyltrans-
ferase 5 affects the stability of E2F1 protein, and
subsequently regulates its function in cell growth and
apoptosis [23]. They have shown that E2F1 protein is
frequently methylated in cancer cells; decreased level ofE2F1 methylation is noted upon DNA damage which
stabilizes E2F1, leading to growth inhibition and apop-
tosis induction. Furthermore, they have found increased
levels of protein arginine methyltransferase 5 accom-
panying with decreased E2F1 protein levels are asso-
ciated with adverse clinical outcome in colorectal cancer.
Since E2F1 gene expression can be affected at tran-
scriptional and post-transcriptional steps, protein expres-
sion probably represents the best way to characterize its
biological role in clinical specimen. In this study, we used
Figure 1 Immunoblotting was performed on representative five pairs of non- tumor (N) lung tissues and tumorous (T) specimens.
Ponceau-S staining was used as control.
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which could potentially avoid the pitfalls associated with
IHC such as staining reaction, operator evaluation, and
comparative evaluation. Our report showed that E2F1
protein expression was significantly higher in tumor spe-
cimens than normal lung tissue. However, E2F1 overex-
pression was not a significant prognostic factor for
overall survival and probability of freedom from recur-
rence in our study. Our results are in consistent with the
report from Volm et al. [18], but different from other
reports [19,20]. The discrepancy of the results among
these 4 studies relating to the clinical significance of
E2F1 expression in NSCLC (as listed in Table 3) could
be due to differences in methodology, sample size, pa-
tient population, etc. However, considering all the data
available on the clinical significance of E2F1 expression
in cancer, it raises a concern for the prognostic role of
E2F1 in NSCLC. For future study of E2F1 in NSCLC, a
more defined and homogenous patient population such
as stage II and III receiving surgery and adjuvant chemo-
therapy will be preferred. Additionally, incorporating
with investigation of proteins regulating E2F1 expression
such as protein arginine methyltransferase 5 may provide
us more insights.
The strength of the study is that we used immunoblot-
ting to quantitate E2F1 protein expression instead of
IHC. There are some limitations of this study that





Tumor 56 0.33 0.04 0.008
Non-tumor 56 0.09 0.02
*The membranes were exposed to NEN Renaissance x-ray film. The linear-
range signal intensity of each specific band on the fluorogram is quantitated
by a densitometric scanning system and comparison of proteins of interest is
performed after normalization to the densitometric scanning of the Ponceau S
staining. The control value of Ponceau S was assigned an arbitrary unit of 1,
and the expression of each protein was denoted as arbitrary densitometry
units (ADU) relative to the corresponding value of Ponceau S stain.sample size is relatively small. A type I error could there-
fore have occurred.
Conclusions
E2F1 protein expression is significantly higher in NSCLC
specimens than non-tumor lung tissue. E2F1 overexpres-
sion does not adversely impact overall survival and prob-
ability of freedom from recurrence.
Methods
Patients and tissue procurement
Fifty-six patients with NSCLC who underwent surgical
resection in Taipei Veterans General Hospital between
January 2001 and June 2003 were enrolled in this study.
The tissue procurement protocol was approved by the
Institutional Review Board, and written informed con-
sent was obtained from all patients. Fresh tumor speci-
mens and adjacent non-tumor lung tissues were
collected in the operating room, snap frozen in liquid ni-
trogen and stored at −80°C until analysis.
Protein extraction and Western blot analysis
Protein extraction and Western blot analysis were per-
formed as previously described [28]. Briefly, frozen tissue
was homogenized and thawed in ice-cold radioimmuno-
precipitation buffer added with 100 μg/ml phenylmethyl-
sulfonyl fluoride, 25 μg/ml Aprotinin, 25 μg/ml
Lupeptin, 10 μg/ml soybean trypsin inhibitor, and 1 mM
sodium orthovandate. The lysate was incubated on ice
for 20 min and then centrifuged at 12,000 rpm for
10 min to sediment the particulate material. Cell lysate
containing 50μg of protein from each sample was
resolved by SDS-polyacrylamide gel electrophoresis
using 8% polyacrylamide. The resolved proteins were
transferred onto Immobilon polyvinyl difluoride mem-
branes (Millipore Corporation, Bedford, MA). Ponceau S
(Sigma Chemical, St. Louis, MO) staining of the mem-
branes was performed to assess the equivalence of sam-
ple loading and gel transfer. Computer densitometry was
used to determine the relative loading. The membranes
were then destained with tap water for several washes.
Figure 2 (A) Cumulative probability of overall survival stratified by E2F1 protein low and high expression. (B) Cumulative probability of
freedom from recurrence stratified by E2F1 protein low and high expression. (log-rank test).
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0.1% Tween 20, the membranes were incubated with
rabbit polyclonal antibody against human E2F1 (Santa
Cruz Biotechnology, Santa Cruz, CA) as the primary
antibody. The blots were then incubated with anti-rabbit
horseradish peroxidase-conjugated secondary antibody









1Last name of the first author/year of publication.
SCC squamous cell carcinoma, IHC immunohistochemistry.The detection of antibody binding was performed by
using Pierce SuperSignal Chemiluminescent detection
reagents with the protocols recommended by the
manufacturer, and blots were exposed to NEN Renais-
sance X-ray film with intensifying screens. The linear-
range signal intensity of E2F1 on the fluorogram was
quantitated by a densitometric scanning system. TheNSCLC






Quantitative RT-PCR 40% Yes
Western blot 38% No
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formed after normalization to the densitometric scan-
ning of the Ponceau S staining. The control value of
Ponceau S staining in each sample was assigned as an
arbitrary densitometry unit (ADU) of 1. The expression
of E2F1 was denoted as ADU relative to the corre-
sponding value of Ponceau S staining. Overexpression
of E2F1 protein was defined as the ADU ratio of E2F1
in tumor vs. non-tumor exceeding 2.
Statistical analysis
The overall survival and probability of freedom from re-
currence were calculated by the Kaplan-Meier method.
The differences of overall survival and probability of
freedom from recurrence were compared between
groups by log-rank test. To compare between groups
with respect to categorical and continuous variables, the
χ2 test or the independent sample t-test was used as
appropriate. Statistical analysis was considered to be sig-
nificant when P <0.05.
Abbreviations
NSCLC: Non-small cell lung cancer; IHC: Immunohistochemistry;
ADU: Arbitrary densitometry unit.
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